Tags: Misfolded Proteins

blog

Trial of First Broad-Spectrum Drug for Neurodegeneration Seeking Volunteers

ADDF grantee Dr. Raymond Scott Turner is recruiting patients for a phase 2 trial of nilotinib—a leukemia drug being tested for treating Alzheimer’s.

announcements

ADDF-Funded Scientists Discover Two Repurposed Drugs With Promise for Alzheimer's and FTD

A team of scientists from the Medical Research Council (MRC) in the UK have found two drugs, which block brain cell death and prevent neurodegeneration in preclinical studies. Their findings were published today in Brain.

announcements

$4 Million in New Grants Support Several First-in-Class Dementia Treatments

We recently awarded eight new grants totaling over $4 million to advance treatments for Alzheimer’s and related dementias. Several of the awards support new approaches to treating these diseases.

blog

Does Verubecestat Signal the End of the Amyloid Hypothesis?

Merck announces the end of another anti-amyloid drug trial, calling in to question the amyloid hypothesis and the fate of other anti-amyloid drugs.

blog

What Does the Failure of Solanezumab Mean?

Eli Lilly announced that its Alzheimer's drug solanezumab failed in its last phase 3 clinical trial. Howard Fillit, MD, discusses what this means, and where we go from here.

announcements

New Clinical Trial Will Test Cancer Drug as Alzheimer's Treatment

Dr. Howard Fillit, the ADDF's Founding Executive Director and Chief Science Officer, says: "The ADDF is proud to support a clinical trial that holds such promise for Alzheimer's patients. This funding is part of our wider initiative to use the knowledge gained from cancer research to advance effective treatments for Alzheimer's."

announcements

Experimental Imaging Agent Reveals Concussion-Linked Brain Disease in Living Brain

Protein tracer shows distinctive pattern of brain protein deposition specific to this disease and typically confirmed after death

announcements

Five New Grants Fund Promising Treatments & Biomarkers

The ADDF awarded five new grants in May and June 2016, totaling nearly $1.5 million.

announcements

Ten New Grants Support Alzheimer's Drug Discovery and Biomarker Development

The ADDF has awarded 10 new grants to researchers developing drugs for neurodegenerative diseases and biomarkers to detect their onset and progression.

announcements

Asceneuron Awarded Alzheimer’s Drug Discovery Foundation Grant

Asceneuron SA, an emerging leader in small molecule therapeutics targeting tauopathies for Alzheimer's and related neurodegenerative diseases, was awarded a $325,000 grant from the ADDF to support the development of its tau modulators.